Cargando…

Promotion of Rat Hepatocarcinogenesis by Praziquantel

Praziquantel, the widely used anti‐helminthic agent, was investigated for hepatocarcinogenesis‐promoting potential using a medium‐term liver bioassay system for carcinogens. F344 male rats were given a single intraperitoneal injection of diethylnitrosamine (DEN, 200 mg/kg) and then starting 2 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirai, Tomoyuki, Joong, Kim Dae, Hakoi, Kazuo, Thamavit, Witaya, Pairojkul, Chawalit, Hoshiya, Toru, Hasegawa, Ryohei, Ito, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1991
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918256/
https://www.ncbi.nlm.nih.gov/pubmed/1683346
http://dx.doi.org/10.1111/j.1349-7006.1991.tb01761.x
Descripción
Sumario:Praziquantel, the widely used anti‐helminthic agent, was investigated for hepatocarcinogenesis‐promoting potential using a medium‐term liver bioassay system for carcinogens. F344 male rats were given a single intraperitoneal injection of diethylnitrosamine (DEN, 200 mg/kg) and then starting 2 weeks later, received praziquantel in the diet at concentrations of 1.5 or 0.5%, or intragastrically at a dose of 1,500 mg/kg once a week for 6 weeks. Control groups received DEN or praziquantel alone. All rats were subjected to two‐thirds partial hepatectomy at week 3 and killed at week 8. Development of glutathione 5‐transferase placental form‐positive foci in the liver was significantly increased in terms of both number and area with the 1.5% dose, while only area was affected by the 0.5% dose. The results thus indicate that praziquantel at high dose has promoting potential in rat hepatocytic tumorigenesis.